VERIGRAFT
Bioengineered, personalized vascular grafts created using advanced 3D printing and tissue engineering technologies.
- CEO / Founder
- Petter Björquist, Ph.D.
- Team Size
- Not publicly disclosed
- Stage
- Active
- Total Funding
- €1.2M
- Latest Round
- Grant
- Key Investors
- Eurostars program
Technology & Products
Key Products
["3D printed arterial grafts","Vascular grafts"]
Technological Advantage
Breakthrough 3D printing techniques enabling highly personalized and biocompatible grafts.
Differentiation
Value Proposition
Personalized 3D printed grafts that mimic natural arteries, offering enhanced biocompatibility, integration, and durability.
How They Differentiate
Focus on personalized, bioengineered vascular grafts with superior biocompatibility compared to conventional synthetic options.
Market & Competition
Target Customers
Medical professionals, vascular surgeons, and patients requiring vascular interventions
Industry Verticals
["Healthcare","Regenerative Medicine","Tissue Engineering"]
Competitors
Aspect Biosystems; Miromatrix; Gore Medical
Growth & Milestones
Growth Metrics
Advancement in preclinical development towards first-in-human trials
Major Milestones
["Secured €1.2M Eurostars grant for breakthrough 3D bioprinting technology","Advancement in preclinical development towards first-in-human trials","Secured SEK 6 million Vinnova grant for AI-based quality improvement in vascular graft manufacturing (Dec 2023)"]
Notable Customers
Sahlgrenska University Hospital